Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e437-44. doi: 10.1016/j.ijrobp.2011.12.085.
To investigate the potential of magnetic resonance imaging (MRI) for accurate assessment of the three-dimensional (166)Ho activity distribution to estimate radiation-absorbed dose distributions in (166)Ho-loaded poly (L-lactic acid) microsphere ((166)Ho-PLLA-MS) liver radioembolization.
MRI, computed tomography (CT), and single photon emission CT (SPECT) experiments were conducted on an anthropomorphic gel phantom with tumor-simulating gel samples and on an excised human tumor-bearing liver, both containing known amounts of (166)Ho-PLLA-MS. Three-dimensional radiation-absorbed dose distributions were estimated at the voxel level by convolving the (166)Ho activity distribution, derived from quantitative MRI data, with a (166)Ho dose point-kernel generated by MCNP (Monte Carlo N-Particle transport code) and from Medical Internal Radiation Dose Pamphlet 17. MRI-based radiation-absorbed dose distributions were qualitatively compared with CT and autoradiography images and quantitatively compared with SPECT-based dose distributions. Both MRI- and SPECT-based activity estimations were validated against dose calibrator measurements.
Evaluation on an anthropomorphic phantom showed that MRI enables accurate assessment of local (166)Ho-PLLA-MS mass and activity distributions, as supported by a regression coefficient of 1.05 and a correlation coefficient of 0.99, relating local MRI-based mass and activity calculations to reference values obtained with a dose calibrator. Estimated MRI-based radiation-absorbed dose distributions of (166)Ho-PLLA-MS in an ex vivo human liver visually showed high correspondence to SPECT-based radiation-absorbed dose distributions. Quantitative analysis revealed that the differences in local and total amounts of (166)Ho-PLLA-MS estimated by MRI, SPECT, and the dose calibrator were within 10%. Excellent agreement was observed between MRI- and SPECT-based dose-volume histograms.
Quantitative MRI was demonstrated to provide accurate three-dimensional (166)Ho-PLLA-MS activity distributions, enabling localized intrahepatic radiation-absorbed dose estimation by convolution with a (166)Ho dose point-kernel for liver radioembolization treatment optimization and evaluation.
研究磁共振成像(MRI)在准确评估三维(166)Ho 活性分布方面的潜力,以估计(166)Ho 负载聚(L-乳酸)微球((166)Ho-PLLA-MS)肝内放射栓塞的辐射吸收剂量分布。
在含有已知量(166)Ho-PLLA-MS 的肿瘤模拟凝胶样本的人体凝胶模型和切除的人肝癌模型上进行 MRI、计算机断层扫描(CT)和单光子发射计算机断层扫描(SPECT)实验。通过将从定量 MRI 数据中获得的(166)Ho 活性分布与由 MCNP(蒙特卡罗 N-粒子传输代码)生成的(166)Ho 剂量点核函数以及由 Medical Internal Radiation Dose Pamphlet 17 生成的(166)Ho 剂量点核函数卷积,在体素水平上估计三维辐射吸收剂量分布。将基于 MRI 的剂量分布与 CT 和放射性自显影图像进行定性比较,并与基于 SPECT 的剂量分布进行定量比较。对基于 MRI 和 SPECT 的活性估算进行验证,与剂量校准器测量值相对照。
在人体模型上的评估表明,MRI 能够准确评估局部(166)Ho-PLLA-MS 质量和活性分布,局部 MRI 计算的质量和活性与剂量校准器获得的参考值之间的回归系数为 1.05,相关系数为 0.99。在离体人肝中,基于 MRI 估算的(166)Ho-PLLA-MS 辐射吸收剂量分布在视觉上与基于 SPECT 的辐射吸收剂量分布高度吻合。定量分析表明,MRI、SPECT 和剂量校准器估计的局部和总量(166)Ho-PLLA-MS 之间的差异在 10%以内。MRI 和 SPECT 之间的剂量体积直方图显示出极好的一致性。
定量 MRI 被证明可以提供准确的三维(166)Ho-PLLA-MS 活性分布,通过与(166)Ho 剂量点核函数卷积,实现局部肝内辐射吸收剂量的估计,从而优化和评估肝内放射栓塞治疗。